Novartis

China expands drug bulk-buy programme, puts pressure on pharma firms

Read more

Novartis’s Sandoz licenses proposed multiple sclerosis biosimilar

Read more

Big Pharma to get bigger, but what about patients?

Read more

Novartis continues to build healthcare talent ecosystem, announces BioCamp 2019

Read more

Novartis announces 26 week gender-neutral parental leave

Read more

US group says Novartis MS drug price out of line with benefit

Read more

Novartis splits drugs business into two

Read more

Novartis’ Afinitor reduces seizures in patients with tuberous sclerosis complex

Read more

Sun Pharma enters Japanese prescription market

Read more

Aurobindo Pharma receives US FDA approval for rivastigmine tartrate capsules

Read more